Chemed (CHE) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Chemed (NYSE:CHE) issued its earnings results on Wednesday. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.05, Bloomberg Earnings reports. Chemed had a net margin of 8.49% and a return on equity of 30.54%. The firm had revenue of $428.35 million for the quarter, compared to analysts’ expectations of $423.83 million. During the same quarter last year, the business earned $2.10 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Chemed updated its FY18 guidance to $10.60-10.85 EPS.

Chemed (NYSE CHE) traded up $4.35 during trading hours on Wednesday, reaching $253.73. 140,326 shares of the company traded hands, compared to its average volume of 97,507. The company has a market capitalization of $4,033.49, a PE ratio of 56.38 and a beta of 1.13. Chemed has a twelve month low of $170.54 and a twelve month high of $275.83. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15.

Several research analysts have recently issued reports on the stock. Oppenheimer raised their target price on shares of Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. ValuEngine cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price on the stock in a report on Thursday, November 2nd. TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Finally, KeyCorp restated a “hold” rating on shares of Chemed in a report on Friday, October 27th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $236.00.

In related news, insider Spencer S. Lee sold 1,000 shares of Chemed stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $238.24, for a total value of $238,240.00. Following the sale, the insider now owns 34,809 shares in the company, valued at $8,292,896.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Patrick Williams sold 11,000 shares of Chemed stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the completion of the sale, the insider now owns 74,857 shares in the company, valued at approximately $18,061,496.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,529 shares of company stock worth $3,741,746. 4.90% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Chemed (CHE) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/02/15/chemed-che-posts-quarterly-earnings-results-beats-estimates-by-0-05-eps.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Earnings History for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply